


What Matters: Patient Priorities

Amy Leitman, JD
President, NTM Info & Research


NTM 
Nontuberculous Mycobacteria
NTM Info & Research






Disclosures

- MannKind: Consultant
- Insmmed: Consultant
- Sepsis Alliance/PCORI Advisory Working Group member
- May discuss medications that are used off-label



Objectives

- Discuss patient experiences related to illness, treatments, and outcomes
- Provide insight into how patient experience data has impacted clinical practice and the development of new therapeutics
- Review tools and resources available to providers, patients, and caregivers to help patients with their care




NTM
Nontuberculous Mycobacteria
NTM Info & Research

By Patients, For Patients




Co-founders:
Patient and
caregiver



The website:
ntminfo.org

The pamphlet: A resource for patients




NTM and Bronchiectasis: The Patient Experience

- Long delays to proper diagnosis¹
- Long, burdensome treatment regimens
- Side effects, some permanent
- Hemoptysis
- Severe cough
- Extreme fatigue
- Shortness of breath
- Unpredictability in day-to-day health and functioning
- Social isolation and stigma

“Ignorance as I'd never heard of bronchiectasis.”


“I was treated three times for chest infections. Two months later they were back each time. Finally sent for X-ray. No face to face appointment and told over the phone. No referral no advice.”

“I visited my GP 22 times in one year, they told me it's anxiety.”



DIAGNOSED: What now?


- What is it?
- Am I contagious?
- How will my life change?
- Will my family help me?
- Will my friends want to be around me?
- Am I getting the correct treatment?
- How long will I be on treatment?
- What are the side effects?
- Do other people have this?
- Where do I find more information?
- Am I going to die from this?



Patient-Focused Drug Development

Patients reported these three symptoms as having the most significant clinical impact on their daily lives:

- Fatigue
- Cough
- Shortness of breath



NTM Research Consortium

ANNALSATS SUPPLEMENT

Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection An NTM Research Consortium Workshop Report

ANNALSATS SUPPLEMENT

Emily Henrick¹, Timothy Akazami², Alan Barker³, Charles L. Daley⁴, David Grittini⁵, Philip Leitman⁶, Amy Letim⁷, Elzbieta Malanga⁸, Theodore K. Marras⁹, Kenneth N. Olivier¹⁰, D. Rebecca Prevots¹¹, Delia Prieto¹², Alexandra L. Quinlan¹³, William Skach¹⁴, John W. Walsh¹⁵, Kevin L. Werhberg¹⁶, and the NTMPC Patient Advisory

¹School of Public Health, Oregon Health & Science University-Portland State University, Portland, Oregon; ²Pulmonary Disease Critical Care Medicine, Mayo Clinic, Rochester, Minnesota; ³Pulmonary Critical Care Medicine, Oregon Health & Science Univ Portland, Oregon; ⁴Department of Medicine, National Jewish Health, Denver, Colorado; ⁵University of Texas Health Science C Tyler, Texas; ⁶NTM Info & Research, Miami, Florida; ⁷CDFO Foundation, Washington, DC; ⁸Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ⁹Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; ¹⁰Subsidiary of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Institutes of Health, Bethesda, Maryland; ¹¹Department of Psychology, University of Miami, Coral Gables, Florida; ¹²Cystic Fibrosis Foundation, Bethesda, Maryland; and ¹³Division of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health & University, Portland, Oregon

Abstract

Nontuberculous mycobacteria (NTM) cause an increasingly important chronic and debilitating lung disease in older adults. Diagnosis is often delayed, although awareness among clinicians and patients is increasing. When necessary, treatment often lasts 18–24 months and consists of two or four antibiotics that can have serious side effects. Relapses are common and consistently require resumption of prolonged therapy. Given the need for improved diagnostic techniques and clinical trials to identify new therapies or to improve existing therapies, a group of North American clinicians and researchers formed the NTM Research Consortium (NTMRC) in 2014. The NTMRC recognized the importance of including the patient voice in determining research priorities for NTM. In November 2015, patients, caregivers, patient advocates, clinical experts, and researchers gathered for a 1-day meeting in Portland, Oregon funded by the Patient-Centered Outcomes Research Institute. The meeting goal was


to define patient-centered research priorities for NTM lung in patients exposed to treatment with the number of people who underwent years of missed diagnosis or inadequate treatment of Participants identified a top research priority: the prevention infection, approval of more effective treatments with fewer side effects and easier administration, understanding the best chest physiotherapy methods, validating and using tools to measure quality of life, developing a disease-specific activity and severity assessment Workshop participants agreed that two complementary objectives are critical to ensure the best achievable outcomes for patient additional decision education to improve screening and diag NTM infections, and (2) development of a geographically diverse network of experts in NTM disease to offer consultation or a therapy after a diagnosis is made.

Keywords: nontuberculous mycobacteria, pulmonary disease, quality of life

Table 1. Nontuberculous mycobacterial lung disease: patient-centered research priorities by topic area


Topic	Priority	Potential Specific Questions and Next Steps
Prevention	1. Strengthen the role of patients in preventing NTM infection or reinfection	Evaluate whether aspiration increases the risk of NTM infection or reinfection
	2. Limit the risk of patient-to-patient transmission of NTM infection in cystic fibrosis clinics	Estimate the risk of person-to-person or indirect transmission in CF clinics Comparative effectiveness of standard and expanded infection control precautions Validate molecular diagnosis techniques being developed by National Jewish Healthcare
Diagnosis	3. Improve the timeliness of diagnosis and develop molecular techniques for rapid species identification and susceptibility	Predictors of positive culture Predictors of meeting ATS disease criteria at diagnosis Identify techniques that improve sputum collection Develop new collection devices
	4. Develop a screening algorithm for patients at risk for pulmonary NTM disease	Evaluate anxiety and depression after diagnosis or during treatment in patients with NTM disease Association between anxiety/depression and poorer treatment adherence Validate NTM Symptom Module [®] tool
Quality of life	5. Develop better methods for sputum collection and testing	Validate correlation between NTM Symptom Module and clinical outcomes
	6. Reduce the impact on patients of anxiety and depression	Develop and evaluate alternative delivery systems for intravenous antibiotics Repurpose existing therapies Develop new, more effective drugs with a shorter therapy duration Comparative effectiveness of exercise and lung clearance devices, taking into account ease of use and affordability Role of therapy in mild cases to prevent disease progression
Treatment	7. Develop an NTM-specific Health-Related Quality of Life tool	Predictors of treatment response
	8. Promote quality-of-life measures for assessing the effectiveness of treatment	Develop a composite index of disease activity or severity that includes microbiological, chest imaging, and quality of life measures Identify biomarkers associated with disease risk, prognosis, or treatment response
Clinical outcomes	9. Reduce the burden of antibiotic treatment for NTM disease	
	10. Develop and test the efficacy of nonpharmacological therapies and holistic medicine approaches	
	11. Improve understanding of who needs or benefits from antibiotic therapy	
	12. Develop a composite measure of disease activity or severity	
	13. Identify and validate biomarkers associated with disease risk, prognosis, and treatment response	

Definition of abbreviations: ATS = American Thoracic Society; CF = cystic fibrosis; NTM = nontuberculous mycobacteria.
*From Reference 22.





Patients: Telling Us How They Really Feel

Top Symptoms Patients Experienced




Most Bothersome Symptoms






What Matters to Patients?

- Quality care
- Effective treatments
- Sound information
- Solid support




True Story...

**“Oh no, I don’t have NTM.
I have MAC.”**



NTM
Nontuberculous Mycobacteria
NTM Info & Research






How You Can Help Your Patients

In addition to taking medicine, help your patient get access to and get the most out of :

- Regular follow-up testing
- Airway clearance and **referral to RT**
- Nutrition and referral to dietitian
- Exercise and fitness, referral to physiotherapy if needed
- Proper rest
- Psychological support mechanisms, referral to therapy
- Clinical trials

Refer them to us at NTM Info & Research for online support, support groups, and information on clinical trials




Which Came First, the Anxiety or the Illness?

Is your patient feeling OK?

DEPRESSION

plays a big role in chronic illness

- How does your patient LOOK?
- Ask your patient how they're FEELING.
- LISTEN to their answers for signs of depression.



Manage Expectations: What to Expect When You're Expecting Side Effects

Peer support can be crucial in helping patients learn from one another about side effects and how to reduce them. Support and knowledge can help reduce their anxiety and increase their likelihood of continuing treatment.

n = 98

Hoarseness/Loss of Voice

Gargling with salt water: 12

Reduce frequency of dosing: 22

Discontinue temporarily: 8


Lozenges: 3

Coughing

Nebulize with bronchodilators: 10

GI side effects

Probiotics: 6



Resources for Patients

ABOUT US CONTACT US PAMPHLET PDF INTERNATIONAL SITES BRONCHIECTASIS DONATE SEARCH ONLINE COMMUNITY

NTM
Nontuberculous Mycobacteria

WHAT IS NTM EXPLORE RESOURCES RESEARCH GET INVOLVED **DONATE NOW**

REGISTER TODAY

MAY 16-17
FAIRMONT GRAND DEL MAR
SAN DIEGO, CA

REGISTER

Did you know most people with NTM also have Bronchiectasis?

ntminfo.org

NTMINFO SUPPORT GROUPS REFERRAL LIST ONLINE COMMUNITY

BRONCHIECTASIS
Info and Research


HOME ABOUT US BRONCHIECTASIS SUPPORT **DONATE**

**AIRWAY CLEARANCE:
AN ESSENTIAL PART OF YOUR TREATMENT**

LEARN MORE

QUICK FACT

bronchiectasisinfo.org



SUPPORT GROUPS FOR NTM AND BRONCHIECTASIS PATIENTS

Did you know most people with NTM also have Bronchiectasis?

[EXPLORE BE](#)




42 GROUPS

37 US

5 Ex-US





A safe space for patients to support one another.

Home

Global Forum

Settings

...s to collaborate, support, and share

[Communities](#) / Community Home

Community Home

Discussion 12.5K

Library 118

Blogs 0

Featured Post

RF: Ask Me Anything Event with Michelle McDonald




Connect

Others with whom you may seek



Engage

Participate in discussions with your peers



Update on NTM Lung Disease and Airway Clearance

2.3K views • 1 month ago



Let's Talk COPD, Bronchiectasis, NTM Lung Disease

650 views • 3 months ago



Meal Planning for individuals with NTM-LD

343 views • 6 months ago



About NTM Info and Research

355 views • 7 months ago



NTM Case Conference Series: Dr. W. Dwight Miller Presenting

304 views • 8 months ago



Rare Disease Day Webinar

191 views • 11 months ago



Building Confidence


52 views • 1 year ago



Healthy Holiday Webinar

38 views • 1 year ago





NTM
Nontuberculous Mycobacteria
NTM Info & Research

“insight”




a patient's perspective




NTM | Bronchiectasis | MAC | Extrapulmonary
SIGN UP for the latest news at ntminfo.org

NTM
Nontuberculous Mycobacteria

UPDATED
for 2024





360Social

Register | Login

BRONCHIECTASIS AND NTM INITIATIVE

BRONCHANDNTM360SOCIAL BRONCHIECTASIS NTM LUNG DISEASE REGISTRY RESEARCH ABOUT US

DONATE NOW

HOME > BRONCHANDNTM360SOCIAL > COMMUNITY DISCUSSIONS > ACTIVITY FEED

- Community Discussions
- Activity Feed
 - Question and Answers
 - Blog
 - Find a Friend
 - Find People Like Me
- How to Participate

Sign In to Participate

Or register to become a member

Welcome to BronchandNTM360social


BronchandNTM360social is an online community for individuals affected by Bronchiectasis and/or NTM, including patients, family members, caregivers, physicians and other healthcare providers. It serves as an online home for these communities and provides a comfortable venue to share thoughts and ideas, ask questions, start discussions, read and comment on blogs, and communicate with peers, thought leaders and community managers.


Bret99 Extreme heat can also trigger asthma symptoms. Here are some valuable tips on surviving asthma during heat emergencies. <https://www.everydayhealth.com/asthma/heat-humidity-and-asthma-symptoms.aspx>

LOOK What I Found everyday HEALTH

Heat, Humidity, and Asthma Symptoms
People with asthma know that hot, humid air can sometimes trigger symptoms like coughing and difficulty breathing. Get helpful tips for managing summer asthma.

Registry






NTM
Nontuberculous Mycobacteria
NTM Info & Research




May 16-17 | FAIRMONT GRAND DEL MAR | San Diego, CA



worldntmday.org

5/16-17: NTM/BE Patient Conference
7/1: World Bronchiectasis Day
8/4: World NTM Day



14411 S. Dixie Hwy, Suite 205
Palmetto Bay, FL 33176

305-901-4NTM (4686)
ntmmail@ntminfo.org
www.ntminfo.org



[Facebook.com/NTMInfo](https://www.facebook.com/NTMInfo)



[@ntminfo](https://www.instagram.com/ntminfo)




[@NTMInfo](https://www.x.com/NTMInfo)



[Youtube.com/ntmir](https://www.youtube.com/ntmir)



[NTMir](https://www.linkedin.com/company/NTMir)



Teamwork Makes the Dream Work



Helga Rosado,
Operations Director



Trisha Kemp,
Community
Engagement Director



Vanessa Hevia,
Office Administrator



Laura Layton,
Community Manager